Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | NOS1 | P29475 | 9/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542003 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL13314521 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL30287655 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL59519 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29776903 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL59520 | 1.00 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Mannitol SCHEMBL21903100 | 0.96 | HSD17B10 (0.68) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Xylitol SCHEMBL18285153 | 0.96 | HSD17B10 (0.68) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| Phosphoric Acid SCHEMBL1443736 | 0.95 | HSD17B10 (0.63) | HSD17B10NOS1AKR1B1 | |
| SCHEMBL12559328 | 0.90 | HSD17B10 (0.66) | HSD17B10NOS1AKR1B1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492220-B2 | Method for the preparation of oligonucleotides | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2025-12-09 | — | — | US | claimed |
| US-12385916-B2 | Serum metabolic biomarkers and kit for detecting drug-resistant tuberculosis | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2025-08-12 | — | — | US | claimed |
| US-20250130240-A1 | MARKER AND DEVICE FOR DIAGNOSING OVERALL HEALTH STATUS OF INDIVIDUAL | T&D Diagnostics Canada Pvt, Ltd. (CA) | 2025-04-24 | — | — | US | claimed |
| EP-4542229-A2 | MARKER AND DEVICE FOR DIAGNOSING OVERALL HEALTH STATUS OF INDIVIDUAL | T&D Diagnostics Canada Pvt, Ltd (CA) | 2025-04-23 | — | — | EP | claimed |
| US-12196753-B2 | Kit for detecting drug-resistant tuberculosis | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2025-01-14 | — | — | US | claimed |
| CN-119215104-A | Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor | 河南中医药大学 | 2024-12-31 | — | — | CN | claimed |
| US-20240295555-A1 | KIT FOR DETECTING DRUG-RESISTANT TUBERCULOSIS | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2024-09-05 | — | — | US | claimed |
| US-20230349900-A1 | SERUM METABOLIC BIOMARKERS AND KIT FOR DETECTING DRUG-RESISTANT TUBERCULOSIS | Zhejiang SUKEAN Pharmaceutical Co., Ltd. (CN) | 2023-11-02 | — | — | US | claimed |
| CN-116913510-A | Training method of prediction model of child autism, prediction device and application thereof | 深圳市康宁医院 | 2023-10-20 | — | — | CN | claimed |
| WO-2023185068-A1 | SERUM METABOLIC MARKERS FOR DETECTING DRUG-RESISTANT PULMONARY TUBERCULOSIS AND KIT THEREOF | 浙江苏可安药业有限公司 | 2023-10-05 | — | — | WO | claimed |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIV (CA) | 2023-06-22 | — | — | US | claimed |
| CN-116178468-A | 5' S-LNA nucleotides and oligonucleotides | 罗氏创新中心哥本哈根有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-114778656-B | Serum metabolic marker for detecting drug-resistant tuberculosis and kit thereof | 浙江苏可安药业有限公司 | 2023-02-14 | — | — | CN | claimed |
| CN-109563121-B | 5' S-LNA nucleotides and oligonucleotides | 罗氏创新中心哥本哈根有限公司 | 2022-12-27 | — | — | CN | claimed |
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. | 2022-11-17 | — | — | US | claimed |
| CN-114778656-A | Serum metabolic marker for detecting drug-resistant tuberculosis and kit thereof | 浙江苏可安药业有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | claimed |
| CN-122050846-A | Ischemic cerebral apoplexy risk assessment model fusing environmental exposure histology and metabonomics biomarkers and model construction method | 生态环境部华南环境科学研究所(生态环境部生态环境应急研究所) | 2026-05-15 | — | — | CN | disclosed |
| CN-114555617-A | Phosphoramidite activators | 富士胶片和光纯药株式会社 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363706-A1 | 5`S-LNA nucleotides and oligonucleotides | DHFR, NSUN3, NSUN2 | HSD17B10 3362/4885NOS1 2096/4885AKR1B1 492/4885 |
| US-11390641-B2 | 5′S-LNA nucleotides and oligonucleotides | NSUN3, NSUN2, DHFR | HSD17B10 3390/4885NOS1 2198/4885AKR1B1 472/4885 |
| US-12492220-B2 | Method for the preparation of oligonucleotides | POLN, POLRMT, POLI | HSD17B10 4366/4885NOS1 3332/4885AKR1B1 3460/4885 |
| US-20230192751-A1 | METHOD FOR THE PREPARATION OF OLIGONUCLEOTIDES | POLN, POLRMT, POLI | HSD17B10 4366/4885NOS1 3332/4885AKR1B1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.